Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Anthem Denies Coverage For Eteplirsen, Citing Lack Of Clinical Efficacy

Executive Summary

The move to deny coverage for an approved orphan drug is ‘highly unusual,' NORD VP says. 'We certainly hope this isn’t going to set a precedent.'


Related Content

Lower Drug Costs Might End Perception US FDA Approval Standards Are Lower
CMS Reminds State Medicaid Agencies: Accelerated Approval Is Still Full Approval
Orphan Drug Pricing Heading To Negotiating Table in US?
NEJM Takes Aim At Expensive Accelerated Approval Drugs Amid Congressional Drug Pricing Debate
Antibacterial Development: Industry Cautious About Role Of Animal Models
Sarepta Winning Payer War Over Duchenne Muscular Dystrophy Drug Coverage
Patient-Centered Promotion? Marathon's Non-Launch Of Emflaza Illustrates Challenge Of New Era
Sarepta Must Balance Exondys 51 Confirmatory Trials And Sales
Sarepta's Eteplirsen Approved After Contentious Internal FDA Debate
CMS Wants To Facilitate Value-Based Discounts For HCV Drugs In Medicaid


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts